ARTL's Losses Widen Amid Soaring R&D, G&A Costs

TL;DR

**ARTL is burning cash at an alarming rate, making it a highly speculative bet despite recent capital raises.**

AI Summary

ARTELO BIOSCIENCES, INC. (ARTL) reported a significant increase in net loss for the nine months ended September 30, 2025, reaching $8,713,000, up from $6,048,000 in the prior year. This 44% increase was driven by a substantial rise in operating expenses, with general and administrative costs nearly doubling to $4,088,000 from $2,779,000, and research and development expenses increasing to $4,530,000 from $3,517,000. The company's cash and cash equivalents decreased to $1,720,000 as of September 30, 2025, from $2,338,000 at December 31, 2024. To address its going concern risk, ARTL raised $4,391,000 from common stock issuance and $737,000 from convertible notes during the nine-month period. A one-for-six reverse stock split was effected on June 13, 2025, reducing outstanding shares from 3,280,000 to approximately 546,667, followed by an increase in authorized shares to 500,000,000. The company also engaged in digital asset purchases of $250,000 and recognized a net change in fair value of digital assets of $75,000.

Why It Matters

ARTL's escalating net losses and dwindling cash reserves signal significant financial instability, raising substantial doubt about its ability to continue as a going concern. For investors, this means high risk and potential for further dilution as the company relies on equity and debt offerings to fund operations, as evidenced by the $4,391,000 raised from common stock issuance. Employees face uncertainty regarding job security if funding efforts falter. Customers and the broader market for lipid-signaling therapeutics could see delays or cessation of promising drug development if ARTL cannot secure sufficient capital to advance its clinical pipeline, especially given the competitive landscape in biopharmaceuticals.

Risk Assessment

Risk Level: high — ARTL reported a net loss of $8,713,000 for the nine months ended September 30, 2025, and had only $1,720,000 in cash and cash equivalents. These conditions, coupled with an accumulated deficit of $58,849,000, raise substantial doubt about the company's ability to continue as a going concern within one year.

Analyst Insight

Investors should exercise extreme caution and consider the significant going concern risk. Monitor future capital raises and clinical trial progress closely, but be prepared for further dilution and potential stock price volatility given the company's current financial state and reliance on external funding.

Financial Highlights

debt To Equity

N/A

revenue

N/A

operating Margin

N/A

total Assets

$4.27M

total Debt

$4.90M

net Income

-$8.71M

eps

-$12.48

gross Margin

N/A

cash Position

$1.72M

revenue Growth

N/A

Key Numbers

• $8.71M — Net Loss (Increased 44% for the nine months ended September 30, 2025, from $6.05M in 2024.)
• $1.72M — Cash and Cash Equivalents (Decreased from $2.34M at December 31, 2024, indicating significant cash burn.)
• $4.53M — Research and Development Expenses (Increased from $3.52M for the nine months ended September 30, 2024.)
• $4.09M — General and Administrative Expenses (Increased from $2.78M for the nine months ended September 30, 2024.)
• $58.85M — Accumulated Deficit (Increased from $50.14M at December 31, 2024, highlighting sustained losses.)
• 1-for-6 — Reverse Stock Split (Effected on June 13, 2025, to adjust share count and potentially boost share price.)
• $4.39M — Proceeds from Common Stock Issuance (Net cash provided by financing activities for the nine months ended September 30, 2025.)
• $737K — Proceeds from Convertible Notes (Net cash provided by financing activities for the nine months ended September 30, 2025.)
• $3.97 — Basic and Diluted Loss Per Share (For the three months ended September 30, 2025, compared to $2.10 in 2024.)
• 2,018,746 — Shares Outstanding (As of November 10, 2025, reflecting post-split and issuance activity.)

Key Players & Entities

• ARTELO BIOSCIENCES, INC. (company) — registrant
• R.F. Lafferty & Co., Inc. (company) — sales agent and underwriter
• Solana (company) — blockchain platform for native token SOL
• $8,713,000 (dollar_amount) — net loss for nine months ended September 30, 2025
• $1,720,000 (dollar_amount) — cash and cash equivalents as of September 30, 2025
• $4,391,000 (dollar_amount) — proceeds from issuance of common stock for cash, net
• $737,000 (dollar_amount) — proceeds from issuance of convertible notes, net
• September 30, 2025 (date) — end of quarterly period
• June 13, 2025 (date) — effective date of one-for-six reverse stock split
• Nevada (state) — state of incorporation

FAQ

Risk Factors

• Increasing Net Loss and Cash Burn [high — financial]: The company reported a net loss of $8.71 million for the nine months ended September 30, 2025, a 44% increase from $6.05 million in the prior year. This escalating loss, coupled with a decrease in cash and cash equivalents to $1.72 million from $2.34 million, indicates a significant cash burn rate and raises concerns about the company's ability to continue as a going concern.
• Reliance on Equity and Debt Financing [medium — financial]: To address its financial challenges, ARTL raised $4.39 million from common stock issuance and $737,000 from convertible notes. This reliance on external financing, especially equity, can dilute existing shareholders and may not be sustainable if losses continue to mount.
• Significant Increase in Operating Expenses [medium — operational]: Operating expenses surged to $8.62 million for the nine months ended September 30, 2025, up from $6.30 million in the prior year. General and administrative costs nearly doubled to $4.09 million, and R&D expenses increased to $4.53 million, suggesting potential inefficiencies or increased investment without corresponding revenue growth.
• Accumulated Deficit [high — financial]: The accumulated deficit grew to $58.85 million as of September 30, 2025, from $50.14 million at December 31, 2024. This substantial and growing deficit highlights a history of unprofitability.
• Digital Asset Investments [low — financial]: The company made digital asset purchases of $250,000 and recognized a net change in fair value of $75,000. While this represents a new area of investment, the volatility and regulatory uncertainty surrounding digital assets introduce additional risks.
• Reverse Stock Split Impact [medium — financial]: A 1-for-6 reverse stock split was executed on June 13, 2025, reducing shares outstanding and potentially impacting market perception and liquidity. While intended to boost share price, it does not address the underlying operational and financial issues.

Industry Context

Artelo Biosciences operates in the highly competitive and capital-intensive biotechnology sector, focusing on developing therapeutics. This industry is characterized by long development cycles, significant R&D investment, and high failure rates. Companies often rely heavily on external funding, including venture capital and public markets, to finance their operations until they achieve regulatory approval and commercialization.

Regulatory Implications

As a biotechnology company, Artelo Biosciences is subject to stringent regulatory oversight from bodies like the FDA. Delays in clinical trials, failure to meet regulatory standards, or changes in regulatory policy can significantly impact development timelines and market access. The company's financial disclosures also need to comply with SEC regulations, including clear reporting of risks and financial performance.

What Investors Should Do

1. Monitor cash burn rate closely: With cash and cash equivalents at $1.72 million and increasing operating expenses, investors should track the company's ability to manage its cash runway and secure further funding.
2. Evaluate R&D pipeline progress: The significant investment in R&D ($4.53 million) requires close monitoring of clinical trial progress and potential milestones to justify the expenditure.
3. Assess the impact of financing activities: Understand the dilution effects of common stock issuances and the terms and potential conversion of convertible notes.
4. Scrutinize G&A expenses: The near doubling of G&A costs warrants investigation into the drivers and efficiency of these expenditures.
5. Consider the long-term viability: Given the increasing net loss and accumulated deficit, investors should assess the company's long-term strategy and potential for profitability.

Key Dates

• 2025-09-30: Nine months ended September 30, 2025 — Reporting period showing a significant increase in net loss and operating expenses, alongside a decrease in cash reserves.
• 2025-06-13: Reverse stock split effected — A 1-for-6 reverse split was implemented, reducing the number of outstanding shares and potentially affecting share price and investor perception.
• 2025-12-31: December 31, 2024 — Prior year-end balance sheet comparison point, showing higher cash reserves and lower liabilities.

Glossary

Accumulated deficit

The total net losses of a company since its inception that have not been offset by profits. (Indicates the company's historical unprofitability, which has worsened significantly in the current period.)

Digital assets

Assets that exist in a digital or electronic form, such as cryptocurrencies or other digital tokens. (Represents a new investment area for the company, introducing potential volatility and regulatory risks.)

Convertible notes

Debt instruments that can be converted into a predetermined amount of the issuer's equity at certain times. (A source of financing for the company, but carries the risk of future dilution upon conversion.)

Going concern

The assumption that a company will continue to operate for the foreseeable future, typically at least the next 12 months. (The company's financial condition, including its cash burn and increasing losses, raises substantial doubt about its ability to continue as a going concern.)

Reverse stock split

A corporate action to reduce the number of outstanding shares of stock, usually to increase the stock's market price. (ARTL implemented a 1-for-6 reverse split, which impacts share count and can affect investor perception.)

Year-Over-Year Comparison

Compared to the prior year's nine-month period, Artelo Biosciences has experienced a significant deterioration in its financial performance. Revenue figures are not explicitly provided for comparison, but the net loss has widened by 44% to $8.71 million. This is primarily driven by a substantial increase in operating expenses, with General and Administrative costs nearly doubling and R&D expenses also rising. The company's cash position has declined, necessitating substantial financing activities through stock and debt issuance. New risks related to digital asset investments have also emerged.

Key Financial Figures

• $0.001 — nge on which registered Common Stock, $0.001 par value per share ARTL The Nasdaq
• $10.45 — se and sale of securities at a price of $10.45 per unit, consisting of: (a) 906,687 sh
• $10.20 — of common stock at an exercise price of $10.20 per share; and (c) three-year warrants
• $50.00 — of common stock at an exercise price of $50.00 per share , for expected aggregate gros
• $4.40 — ommon stock at a price to the public of $4.40 per share, and (ii) pre-funded warrants
• $4.399 — per share, at a price to the public of $4.399 per pre-funded warrant , for aggregate

Filing Documents

• artl_10q.htm (10-Q) — 843KB
• artl_ex311.htm (EX-31.1) — 12KB
• artl_ex312.htm (EX-31.2) — 10KB
• artl_ex321.htm (EX-32.1) — 5KB
• artl_ex322.htm (EX-32.2) — 4KB
• 0001640334-25-002022.txt ( ) — 4024KB
• artl-20250930.xsd (EX-101.SCH) — 39KB
• artl-20250930_lab.xml (EX-101.LAB) — 252KB
• artl-20250930_cal.xml (EX-101.CAL) — 38KB
• artl-20250930_pre.xml (EX-101.PRE) — 220KB
• artl-20250930_def.xml (EX-101.DEF) — 135KB
• artl_10q_htm.xml (XML) — 547KB

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION Item 1.

Financial Statements

Financial Statements 3 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 20 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 33 Item 4.

Controls and Procedures

Controls and Procedures 33

- OTHER INFORMATION

PART II - OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 34 Item 1A.

Risk Factors

Risk Factors 34 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 34 Item 3. Defaults Upon Senior Securities 34 Item 4. Mine Safety Disclosures 34 Item 5. Other Information 34 Item 6. Exhibits 35

SIGNATURES

SIGNATURES 36 2 Table of Contents

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements ARTELO BIOSCIENCES, INC. Consolidated Balance Sheets (Unaudited) (In thousands, except share data) September 30, December 31, 2025 2024 ASSETS Current Assets Cash and cash equivalents $ 1,720 $ 2,338 Prepaid expenses and other current assets 107 219 Total Current Assets 1,827 2,557 Operating lease right-of-use assets 73 99 Digital assets 325 - Intangible asset 2,039 2,039 Other assets 3 3 TOTAL ASSETS $ 4,267 $ 4,698 LIABILITIES AND STOCKHOLDERS' EQUITY Current Liabilities Accounts payable and accrued liabilities $ 3,868 $ 1,676 Due to related parties 32 61 Operating lease liabilities - current portion 39 35 Accrued interest - convertible notes 46 - Convertible notes 875 - Total Current Liabilities 4,860 1,772 Operating lease liabilities 40 69 TOTAL LIABILITIES 4,900 1,841 STOCKHOLDERS' EQUITY Preferred Stock, par value $ 0.001 , 69,444 shares authorized, 0 shares issued and outstanding as of September 30, 2025 and December 31, 2024 - - Common Stock, par value $ 0.001 , 500,000,000 shares authorized and 1,555,493 and 567,582 shares issued and outstanding as of September 30, 2025, and December 31, 2024, respectively 2 1 Additional paid-in capital 58,491 53,194 Accumulated deficit ( 58,849 ) ( 50,136 ) Accumulated other comprehensive loss ( 277 ) ( 202 ) TOTAL STOCKHOLDERS' (DEFICIT) EQUITY ( 633 ) 2,857 TOTAL LIABILITIES AND STOCKHOLDERS' (DEFICIT) EQUITY $ 4,267 $ 4,698 3 Table of Contents ARTELO BIOSCIENCES, INC. Consolidated Statements of Operations and Comprehensive Loss (Unaudited) (In thousands, except per share data) Three Months Ended Nine Months Ended September 30, September 30, 2025 2024 2025 2024 OPERATING EXPENSES General and administrative $ 1,814 $ 870 $ 4,088 $ 2,779 Research and development 1,275 325 4,530 3,517 Total operating exp

View Full Filing

View this 10-Q filing on SEC EDGAR